1227210-46-9

Usage

Chemical Class

Pyrazole derivatives

Explanation

1-methyl-3-nitro-1H-pyrazole-5-methanol belongs to the family of pyrazole derivatives, which are heterocyclic compounds with a five-membered ring containing one nitrogen atom and one carbon atom.

Explanation

This chemical compound contains a nitro group (-NO2) at the 3-position of the pyrazole ring, which is known for its diverse range of biological activities and potential applications in the pharmaceutical industry.

Explanation

A methyl group (-CH3) is attached to the 1-position of the pyrazole ring, contributing to the compound's structure and properties.

Explanation

The compound contains a hydroxyl group (-OH) at the 5-position, which can form hydrogen bonds and influence the compound's solubility, reactivity, and other properties.
5. Potential Pharmaceutical Applications

Explanation

Due to the presence of a nitro group and other functional groups, 1-methyl-3-nitro-1H-pyrazole-5-methanol has potential applications in the pharmaceutical industry, but further research and testing are needed to fully understand its properties and uses.

Explanation

Nitro compounds, such as 1-methyl-3-nitro-1H-pyrazole-5-methanol, can be potentially hazardous due to their reactivity and the possibility of explosive decomposition. It is important to handle these compounds with care and follow appropriate safety precautions.

Nitro Compound

Presence of a nitro group

Methyl Group

Position 1 substitution

Hydroxyl Group

Position 5 substitution

Potential Hazards

Handling precautions

Upstream product

• 181585-93-3 5-nitro-2H-pyrazole-3-carboxylic acid methyl ester 
• 74-88-4 methyl iodide 
• 181585-93-3 5-nitro-1H-pyrazole-3-carboxylic acid methyl ester 
• 177409-38-0 2-methyl-5-nitro-2H-pyrazole-3-carboxylic acid methyl ester 

Downstream Products

• 1360055-92-0 2-{3-[5-(5-Azetidin-1-ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2-hydroxymethyl-phenyl}-6-tert-butyl-8-fluoro-2H-phthalazin-1-one 
• 1360055-72-6 2-(2-{ 3-[5-(5-azetidin-1-ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl]-2-hydroxymethyl-phenyl}-8-fluoro-1-oxo-1,2-dihydroisoquinolin-6-yl)-2-methyl-propionitrile 
• 1612853-60-7 2-(2-{3-[5-(5-azetidin-1-ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl]-2-formylphenyl}-8-fluoro-1-oxo-1,2-dihydroisoquinolin-6-yl)-2-methyl-propionitrile 
• 1328640-82-9 5-(methoxymethyl)-1-methyl-1H-pyrazol-3-amine 

Relevant academic research and scientific papers

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations. RB is a radical selected from the group consisting of (b-1) to (b-4).

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses the Btk inhibitor compounds 6-tert-Butyl-8-fluoro-2-{3- hydroxymethyl-4-[1-methyl-5-(1'-methyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-6-ylamino)- 6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-2H-phthalazin-1-one, 2-(2-{3-[5-(5-Azetidin-1- ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2- hydroxymethyl-phenyl}-8-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-propionitrile, and 6-tert-Butyl-2-[2-hydroxymethyl-3-(5-{5-[(2-methoxy-ethylamino)-methyl]-pyridin-2- ylamino}-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl]-3,4-dihydro-2H-isoquinolin-1-one, formulations thereof, and methods of treatment of asthma, as described herein.

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS

Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, ar